At week 16, Mean Western Ontario and McMasters Universities Osteoarthritis Index pain scores (0-10, no to extreme pain) decreased from 7.1 to 3.6 in the tanezumab 2.5+2.5mg group; 7.3 to 3.6 in the tanezumab 2.5+5mg, group; and 7.3 to 4.4 in the placebo group (least squares mean differences [95% CI] vs placebo were −0.60 [−1.07 to −0.13; P = .01] for tanezumab 2.5 mg, and −0.73 [−1.20 to −0.26; P = .002] for tanezumab, 2.5/5 mg). A related editorial highlights that improvements were modest and tanezumab-treated patients had more joint safety events and total joint replacements.